Psychiatric comorbidity in treatment seeking substance use disorder patients with and without ADHD; results of the IASP study.
Addiction. 2013 Oct 4;
Authors: van Emmerik-van Oortmerssen K, van de Glind G, Koeter MW, Allsop S, Auriacombe M, Barta C, Bu ET, Burren Y, Carpentier PJ, Carruthers S, Casas M, Demetrovics Z, Dom G, Faraone SV, Fatseas M, Franck J, Johnson B, Kapitány-Fövény M, Kaye S, Konstenius M, Levin FR, Moggi F, Møller M, Ramos-Quiroga JA, Schillinger A, Skutle A, Verspreet S, IASP research group, van den Brink W, Schoevers RA
Abstract
AIMS: To determine comorbidity patterns in treatment-seeking substance use disorder (SUD) patients with and without adult Attention Deficit Hyperactivity Disorder (ADHD) with emphasis on subgroups defined by ADHD subtype, taking into account differences related to gender and primary substance of abuse.
DESIGN: Data were obtained from the cross-sectional International ADHD in Substance use disorder Prevalence (IASP) study.
SETTING: 47 centers of SUD treatment in 10 countries.
PARTICIPANTS: 1,205 treatment-seeking SUD patients.
MEASUREMENTS: Structured diagnostic assessments were used for all disorders: presence of ADHD was assessed with the Conners’ Adult ADHD Diagnostic Interview for DSM-IV (CAADID), presence of antisocial personality disorder (ASPD), major depression (MD), and (hypo)manic episode (HME) was assessed with the Mini International Neuropsychiatric Interview-Plus (MINI Plus) and the presence of borderline personality disorder (BPD) was assessed with the SCID II.
FINDINGS: The prevalence of DSM-IV adult ADHD in this SUD sample was 13.9%. ASPD (OR=2.8, 95% CI 1.8-4.2), BPD (OR=7.0, 95% CI 3.1-15.6 for alcohol; OR=3.4, 95% CI 1.8-6.4 for drugs), MD in patients with alcohol as primary substance of abuse (OR=4.1, 95% CI 2.1-7.8) and HME (OR=4.3, 95% CI 2.1-8.7) were all more prevalent in ADHD+ compared with ADHD- patients (p<0.001). These results also indicate increased levels of BPD and MD for alcohol compared with drugs as primary substance of abuse. Comorbidity patterns differed between ADHD subtypes with increased MD in the inattentive and combined subtype (p<.01), increased HME and ASPD in the hyperactive/impulsive (p<.01) and combined subtypes (p<.001) and increased BPD in all subtypes (p<.001) compared with SUD patients without ADHD. 75% of ADHD patients had at least one additional comorbid disorder compared with 37% of SUD patients without ADHD.
CONCLUSIONS: Treatment-seeking substance use disorder patients with Attention Deficit Hyperactivity Disorder are at a very high risk for additional externalizing disorders.
PMID: 24118292 [PubMed – as supplied by publisher]
via http://www.ncbi.nlm.nih.gov/pubmed/24118292?dopt=Abstract
